Evidence map›Paper›PMID 29031392›Full record

ArticleProstaglandins, leukotrienes, and essential fatty acids2017

Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus.

Robert C Block, Ashley Holub, Amir Abdolahi, Xin M Tu, Shaker A Mousa, Michael N Oda

Open access · bronzeAbstract read
In one paragraph

Article in Prostaglandins, leukotrienes, and essential fatty acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial.Journal of the American College of Emergency Physicians open · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Robert C BlockDepartment of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States. Electronic address: robert_block@urmc.rochester.edu.
Ashley HolubDepartment of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.
Amir AbdolahiDepartment of Acute Care Solutions, Philips Research North America, United States.
Xin M TuDivision of Biostatistics & Bioinformatics in the Department of Family Medicine and Public Health, University of California School of Medicine, San Diego, CA, United States.
Shaker A MousaPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, United States.
Michael N OdaChildren's Hospital Oakland Research Institute, Oakland, CA, United States.
University of Rochester · USAlbany College of Pharmacy and Health Sciences · USPhilips (United States) · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
RESEARCH TRAINING IN PREVENTIVE CARDIOLOGYT32HL007937 · NHLBI · UNIVERSITY OF ROCHESTER · PI LOWENSTEIN, CHARLES J · 2000 to 2014
$7.1M
The University of Rochester's Clinical and Translational Science InstituteKL2RR024136 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$4.3M
NCATS NIH HHS UL1 TR001442NCRR NIH HHS KL2 RR024136NHLBI NIH HHS T32 HL007937
6 · The paper itself

Abstract

background/synopsisLow-dose aspirin is an effective drug for the prevention of cardiovascular disease (CVD) events but individuals with diabetes mellitus can be subject to 'aspirin resistance'. Thus, aspirin's effect in these individuals is controversial. Higher blood levels of seafood-derived omega-3 polyunsaturated fatty acids (ω3) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also have beneficial effects in reducing risk of CVD events but few studies have examined the interaction of plasma EPA and DHA with aspirin ingestion. OBJECTIVE/PURPOSE: Our study examined the combinatory effects of EPA, DHA, and aspirin ingestion on HDL-cholesterol (HDL-C) and apoA-I exchange (shown to be associated with CVD event risk).

methods30 adults with Type 2 diabetes mellitus ingested aspirin (81mg/day) for 7 consecutive days, EPA+DHA (2.6g/day) for 28 days, then both for 7 days. Plasma was collected at baseline and at 5 subsequent visits including 4h after each aspirin ingestion. Mixed model methods were used to determine HDL-C-concentrations and apoA-I exchange compared to the baseline visit values. LOWESS curves were used for non-linear analyses of outcomes to help discern change patterns, which was followed by piecewise linear functions for formal testing of curvilinear relationships.

resultsSignificant changes (p < 0.05) compared to baseline in both HDL-C-concentrations and apoA-I exchange were present at different times. After 7 days of aspirin-only ingestion, apoA-I exchange was significantly modified by increasing levels of DHA concentration, with increased apoA-I exchange observed up until log(DHA) of 4.6 and decreased exchange thereafter (p = 0.03). These LOWESS curve effects were not observed for EPA or HDL-C (p > 0.05). Aspirin's effects on apoA-I exchange were the greatest when EPA or DHA concentrations were moderate compared to high or low. Comparison of EPA, DHA, and EPA+DHA LOWESS curves, demonstrated that the majority of the effect is due to DHA.

conclusionOur results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus.

Indexed as

AdultAgedApolipoprotein A-IAspirinCholesterol, HDLDiabetes Mellitus, Type 2Docosahexaenoic AcidsDose-Response Relationship, DrugEicosapentaenoic AcidFemaleHumansMaleMiddle AgedTriglyceridesAPOA1 protein, humanApolipoprotein A-IAspirinCholesterol, HDLDocosahexaenoic AcidsEicosapentaenoic AcidTriglyceridesApoAAspirinDiabetes mellitusDocosahexaenoic acidEicosapentaenoic acidHigh density lipoprotein

Identifiers

PMID29031392
PMCPMC5683419
OpenAlexW2753549266

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.